- Home
- ACAD vs HHH Comparison
ACAD vs HHH Comparison
Compare ACAD & HHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- HHH
- Stock Information
- Founded
- ACAD 1993
- HHH 2010
- Country
- ACAD United States
- HHH United States
- Employees
- ACAD N/A
- HHH N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- HHH Real Estate Investment Trusts
- Sector
- ACAD Health Care
- HHH Real Estate
- Exchange
- ACAD Nasdaq
- HHH Nasdaq
- Market Cap
- ACAD 4.0B
- HHH 3.3B
- IPO Year
- ACAD 2004
- HHH N/A
- Fundamental
- Price
- ACAD $25.99
- HHH $75.91
- Analyst Decision
- ACAD Buy
- HHH Buy
- Analyst Count
- ACAD 20
- HHH 2
- Target Price
- ACAD $28.63
- HHH $85.00
- AVG Volume (30 Days)
- ACAD 2.0M
- HHH 358.3K
- Earning Date
- ACAD 08-06-2025
- HHH 08-06-2025
- Dividend Yield
- ACAD N/A
- HHH N/A
- EPS Growth
- ACAD 615.00
- HHH N/A
- EPS
- ACAD 1.33
- HHH 4.43
- Revenue
- ACAD $1,018,885,000.00
- HHH $1,770,945,000.00
- Revenue This Year
- ACAD $14.01
- HHH N/A
- Revenue Next Year
- ACAD $11.72
- HHH $22.53
- P/E Ratio
- ACAD $19.61
- HHH $15.17
- Revenue Growth
- ACAD 14.41
- HHH 80.45
- 52 Week Low
- ACAD $13.40
- HHH $61.41
- 52 Week High
- ACAD $26.65
- HHH $87.77
- Technical
- Relative Strength Index (RSI)
- ACAD 62.55
- HHH 64.78
- Support Level
- ACAD $25.14
- HHH $74.43
- Resistance Level
- ACAD $26.65
- HHH $75.85
- Average True Range (ATR)
- ACAD 0.67
- HHH 1.29
- MACD
- ACAD 0.04
- HHH 0.22
- Stochastic Oscillator
- ACAD 70.27
- HHH 100.00
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About HHH Howard Hughes Holdings Inc.
Howard Hughes Holdings Inc owns, manages, and develops commercial, residential, and mixed-use real estate throughout the USA. Its portfolio is strategically positioned to meet and accelerate development based on market demand, resulting in one of the strongest real estate platforms in the country. It operates through four business segments: Operating Assets, MPCs, Strategic Developments and Seaport.